hemotune
Founded Year
2017Stage
Series B | AliveTotal Raised
$14.57MLast Raised
$7.58M | 9 mos agohemotune's Product Videos
Compete with hemotune?
Ensure that your company and products are accurately represented on our platform.
hemotune's Products & Differentiators
HemoDevice
Reusable active medical device similar to a dialysis machine for magnetic blood purification. It pumps blood outside of the body and adds and removes magnetic beads to/from the blood. The HemoDevice can be used for different indications.
Expert Collections containing hemotune
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
hemotune is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,605 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
hemotune Patents
hemotune has filed 1 patent.
The 3 most popular patent topics include:
- Causes of death
- Human female endocrine system
- Intensive care medicine
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/18/2020 | Intensive care medicine, Human female endocrine system, Rare diseases, Causes of death, Syndromes | Application |
Application Date | 9/18/2020 |
|---|---|
Grant Date | |
Title | |
Related Topics | Intensive care medicine, Human female endocrine system, Rare diseases, Causes of death, Syndromes |
Status | Application |
Latest hemotune News
Nov 15, 2022
Five high-tech startup competitions collected awards from various startup competitions worldwide including the US, the Nordics, Singapore. Fintech startup scored a spot in Global Fintech Hackcelerator while Hemotune’s solution got recognition from Frost & Sullivan, one of the most recognized market research companies.
hemotune Frequently Asked Questions (FAQ)
When was hemotune founded?
hemotune was founded in 2017.
Where is hemotune's headquarters?
hemotune's headquarters is located at Wagistrasse 27, Schlieren.
What is hemotune's latest funding round?
hemotune's latest funding round is Series B.
How much did hemotune raise?
hemotune raised a total of $14.57M.
Who are the investors of hemotune?
Investors of hemotune include Occident Group, Zurcher Kantonalbank, Hemex, VP Venture Partners, Venturelab and 10 more.
Who are hemotune's competitors?
Competitors of hemotune include ExThera Medical and 3 more.
What products does hemotune offer?
hemotune's products include HemoDevice and 2 more.
Who are hemotune's customers?
Customers of hemotune include University Hospital Bern.
Compare hemotune to Competitors
MediSieve is developing a magnetic blood filter able to remove disease-causing agents from blood to treat blood-borne diseases. Similar to dialysis, blood is circulated through a magnetic blood filter which captures and removes targets based on their magnetic properties.
PATH EX is developing an extracorporeal blood cleansing device designed to selectively remove pathogens, including multi-drug resistant bacteria, and endotoxins from circulating blood.
ExThera Medical is a privately-held medical device company developing a single-use blood filter capable of capturing and removing a broad range of bacteria, viruses, parasites, toxins, and other harmful substances from whole blood. The company intends to develop therapeutic products to treat patients in the clinic or hospital, as well as devices that purify donated, banked blood prophylactically before transfusion.
BOA Biomedical develops a medical device that rapidly diagnoses and treats infectious diseases, with a special focus on sepsis and antibiotic-resistant pathogens.
CytoSorbents (NASDAQ: CTSO) is a New Jersey-based, critical care immunotherapy company specializing in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients.
Cheetah Medical is a provider in non-invasive Cardiac Output and Hemodynamic monitoring. The company is focused on development and commercialization of an accurate non-invasive solution for the monitoring of critically ill patients. Cheetah Medical's NICOM Noninvasive Hemodynamic Monitoring System is based on the company's BIOREACTANCE technology. On September 10, 2019, Cheetah Medical was acquired by Baxter at a valuation of between $190M and $230M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.